Oxurion NV OXUR-BE:Euronext Brussels

*Data is delayed | EUR
Last | 05/20/22 CEST
0.61quote price arrow up+0.008 (+1.33%)
Volume
31,413
52 week range
0.52 - 2.63
Loading...
  • Open0.612
  • Day High0.64
  • Day Low0.61
  • Prev Close0.602
  • 52 Week High2.63
  • 52 Week High Date06/18/21
  • 52 Week Low0.52
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap24.74M
  • Shares Out38.41M
  • 10 Day Average Volume137,929.27
  • Dividend-
  • Dividend Yield-
  • Beta1.1
  • YTD % Change-66.41

KEY STATS

  • Open0.612
  • Day High0.64
  • Day Low0.61
  • Prev Close0.602
  • 52 Week High2.63
  • 52 Week High Date06/18/21
  • 52 Week Low0.52
  • 52 Week Low Date05/09/22
  • Market Cap24.74M
  • Shares Out38.41M
  • 10 Day Average Volume137,929.27
  • Dividend-
  • Dividend Yield-
  • Beta1.1
  • YTD % Change-66.41

RATIOS/PROFITABILITY

  • EPS (TTM)-0.76
  • P/E (TTM)-0.80
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oxurion NV

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States....
Patrik De Haes M.D.
Non-Executive Chairman of the Board
Tom Graney
Chief Executive Officer, Chief Financial Officer, Executive Director
Hanne Callewaert
Chief Operating Officer, Member of the Executive Board
Address
Gaston Geenslaan 1
Heverlee
3001
Belgium